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 TO THE EDITOR
ng  pharmacological options for
ea  relief; the need for full,
studies  of  opioid  efﬁcacy  or  safety.5 In  most  people,  opioid
efﬁcacy is  high  in  the  short  term  but  diminishes  over  6  weeksmon
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sal  of the evidence
itor,
 with  interest  the  review  on  strategies  to  relieve
 in  patients  with  advanced  chronic  respiratory  dis-
mbrosino  and  Fracchia.1 Given  the  clinical  need  for
ological options  for  dyspnoea  relief,  we  would  like
ent  on  some  important  aspects  that  we  feel  merit
lariﬁcation.
eview  comments  on  inhaled  furosemide  as  a  poten-
 for  relieving  dyspnoea  and  refers  to  our  RCT
y  volunteers2 which  showed  signiﬁcant  relief  of
ntally-induced air  hunger.  The  review  stipulates
 was  ‘‘a  ﬁnding  not  conﬁrmed  later  even  at  higher
The  comment  is  misleading,  implying  that  higher-
dies  were  completed  subsequent  to  ours  and  that
ngs  were  incongruous.  Our  study2 was  published
e  higher-dose  studies.  The  controlled  delivery  of
as  associated  with  greater  air  hunger  relief3 com-
 what  we  found  with  uncontrolled  delivery  of
ean  ±  SE:  −17  ±  3  versus  −11  ±  5%VAS).  However,
ter  relief  in  the  higher-dose  study  was  offset  by
placebo  effect  (−13  ±  4  versus  −2.5  ±  4%VAS).  The
d placebo  effect  in  the  higher-dose  study  can  be
d by  differences  in  study  design.
 there  is  high  variability  in  dyspnoea  relief  in  all
d studies  of  inhaled  furosemide,  there  is  poten-
t  to  form  a  viable  treatment  option  for  the  most
nt form  of  dyspnoea  if  the  sources  of  variability  are
d. Potential  sources  of  variability  include,  i)  site
deposition  in  the  lungs  ii)  rate  of  extinction  from
 iii)  lack  of  information  on  the  quality  of  dyspnoea
d  iv)  use  of  a  dyspnoea  model  that  is  not  focussed
unger’.  More  research  with  inhaled  furosemide  is
given  that  it  is  safe,  inexpensive  and  underpinned
ned  physiological  mechanism  of  action.
iscussion  by  Ambrosino  and  Fracchia  on  the  use
s  for  dyspnoea  relief  is  also  misleading  and  fails
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vents  with  no  improvement  in  symptoms.5 We  sug-
eme  caution  is  necessary  for  prescription  of  opioid
on for  breathlessness  because,  i)  opioids  increase
death  in  people  with  lung  conditions,4 ii)  people
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ly  to  have  problems  with  dependency  and  failure
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